Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published today in JAMA Oncology by researchers at The University of Texas MD Anderson Cancer Center and Yale Cancer Center.
Daniel M. Geynisman, MD, is being announced the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman, Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has a long history of working with NCCN in a variety of roles.
A new report from the American Association for Cancer Research explains the major drivers of cancer disparities and which groups are affected most. UChicago Medicine is prioritizing research initiatives that promote cancer equity.
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Today marks a significant milestone in cancer care with the introduction of bipartisan federal legislation that would revolutionize Medicare reimbursement for radiation therapy.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with a significant portion of these deaths attributed to the aggressive nature of the disease and its resistance to traditional treatments. The study's findings offer a promising new avenue for therapeutic intervention by targeting the interaction between neutrophils and lung cancer cells, potentially improving patient outcomes.
By completely or even partially depleting a protein called midnolin in B cells, UT Southwestern Medical Center researchers suppressed leukemia and lymphoma in a mouse model genetically prone to these cancers. Their findings, reported in the Journal of Experimental Medicine, could lead to new treatments for these diseases that avoid the serious side effects of current therapies.
Michelle Usher knew something was wrong when she became too tired to hold a paint brush or read a book. The avid oil painter and voracious reader could devour 100 novels and memoirs a year until late 2022, when overwhelming exhaustion set in.
Chemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most common forms: non-Hodgkin and Hodgkin. But alternatives to chemotherapy are developing, as first-line treatments and as backup options, explains Stephen Ansell, M.D., Ph.D., hematology chair and hematologic oncologist at the Mayo Clinic Comprehensive Cancer Center.
A new survey from the American Academy of Dermatology revealed that Generation Z adults, ages 18-25, are at risk for skin cancer due to increasing rates of tanning and burning. To encourage safe sun habits, the AAD is shining a spotlight on the ways that people can protect themselves from the most common and one of the most preventable types of cancer — skin cancer — this May for Skin Cancer Awareness Month.
20221027104337.jpg&width=300&height=300)
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill.
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.
At the University of Alberta, researchers explored how intense ultrasound can release biological indicators of disease from cells. These biomarkers can help identify different types of cancer and inform the subsequent therapy.
Randomized controlled trials have long been the gold standard for evaluating new therapies. But for pediatric brain tumors, it can be difficult—if not impossible—to enroll the large numbers of patients needed for these studies.
Researchers from the Cancer Science Institute of Singapore (CSI) at the National University of Singapore (NUS), have achieved breakthroughs in understanding relapse after chemotherapy for a type of cancer known as diffuse large B-cell lymphoma (DLBCL).
Showing results
1–20 of 24782
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
